Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? [electronic resource]
Producer: 20200803Description: 1751-1759 p. digitalISSN:- 1569-8041
- Antineoplastic Agents, Immunological -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- B7-H1 Antigen -- antagonists & inhibitors
- CTLA-4 Antigen -- antagonists & inhibitors
- Clinical Trials, Phase I as Topic -- standards
- Dose-Response Relationship, Drug
- Humans
- Maximum Tolerated Dose
- Neoplasms -- drug therapy
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Protein Kinase Inhibitors -- administration & dosage
- Research Design -- standards
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.